We here succeeded in demonstrating for the first time that RAR signaling in human T cells is targets for improving the clinical efficacy of cancer immunotherapies such as adoptive TCR- or chimeric antigen receptor-transduced T-cell therapy, whose clinical effect is largely dependent upon the amount of memory and undifferentiated T cells (36, 67). The gene discussed is RARA; the disease is cancer.